TABLE 1.
Prevalence at baseline and incidence of resistance-associated mutations within the HBV polymerase during 3TC treatment as determined by direct sequencing of PCR products
| Mutation within HBV polymerase (rt) | Cumulative incidence rate during 3TC treatment (%) [no. with HBV genotype A/no. with HBV genotype D]
|
||
|---|---|---|---|
| At baseline (n = 96) | After 1 yr (n = 96) | After 2 yr (n = 92) | |
| L180M | 0 (0) | 10 (10) [8/2] | 26 (28) [19/7] |
| M204I (YIDD) | 0 (0) | 5 (5) [2/3] | 15 (16) [5/10] |
| M204V (YVDD) | 0 (0) | 14 (14) [14/0] | 26 (28) [21/5] |
| V207I | 1 (1)a | 0 (0)b | 1 (1) [1/0] |
a
This patient (case patient) carried HBV genotype A.
b
The patient with an rtV207I mutation at baseline (case patient) was excluded.